PCD expert talks: Understanding natural variability in lung function: insights from the PROVALF-PCD cohort
What is this session about?
The PROVALF-PCD (Prospective Observational Multicentre Study on Variability of Lung Function in Stable PCD Patients) study is a multicentre, longitudinal project designed to better understand how lung function naturally changes over time in people with PCD. The cohort includes 252 patients recruited from 19 centres across 12 countries, making it one of the largest collaborative efforts in this rare disease. Over the course of the study, we collected over 1,000 FEV1 measurements from patients in stable state, during routine clinical follow-up, spanning a period of 15 months.
The study examined the extent and patterns of natural changes in lung function within each person, when these changes can be considered physiologically relevant, and what this might mean for disease monitoring, treatment decisions, and clinical trial design. This talk will discuss how PROVALF-PCD provides insights that are relevant for patients, in understanding their own health journeys, for clinicians, in shaping management strategies, and for researchers, in designing future studies.
About the speakers:
Bruna Rubbo is a senior lecturer at the University of Southampton. She co-chaired ‘BEAT-PCD COST Action’ WP 4 Outcome measures from 2017 to 2019 and currently chairs BEAT-PCD WP5 Clinical Outcome Measures. Her research focuses on the epidemiology of PCD, including improving diagnosis, understanding genotype–phenotype relationships, and evaluating lung function and clinical outcomes, with the aim of advancing patient care and developing robust outcome measures for both clinical practice and research.

